13 May 2024 - Women with endometrial cancer and people with itching associated with chronic kidney disease will benefit from new lifechanging medicines added to the Pharmaceutical Benefits Scheme from May 1.

Dostarlimab (Jemperli) will be listed for the first time, for the treatment of women battling primary advanced or first recurrent endometrial cancer that is classified as mismatch repair deficient, in combination with chemotherapy.

Read Minister for Health press release